ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

CD BioSciences Introduces New Cell Death Solutions to Facilitate Research

By: Get News
CD BioSciences has recently launched a series of research solutions covering all aspects of cell death studies, particularly programmed cell death.

New York, USA - February 27, 2023 - CD BioSciences, a US-based CRO serving the global life science research community, has recently launched a series of research solutions covering all aspects of cell death studies, particularly programmed cell death, which is important for morphogenesis development and the maintenance of cell proliferation and tissue homeostasis in organs.

Cell death is an essential event in the life cycle of multicellular organisms. Programmed cell death (PCD) was first described by C. Vogt in the mid-19th century by observing the morphology of dying cells during amphibian metamorphosis. There are three major forms of PCD in mammalian cells: apoptosis, autophagic cell death, and regulated necrosis (sometimes called necroptosis).

Apoptosis can be activated through extrinsic (death receptor-dependent) or intrinsic (mitochondria-dependent) pathways. Apoptotic cell death may or may not require the activation of cytosolic proteases called caspases. Autophagy has an important homeostatic role in cells, mediating the removal of dysfunctional or damaged organelles, thereby allowing the recycling of cellular building blocks. However, unrestricted autophagy kills cells. Recent studies have shown that necrosis, which depends on the activation of the kinases RIP1 and RIP3, is a major form of programmed cell death with roles in development and immunity.

Cell death is essential for homeostasis, and the imbalance of cell death can cause serious diseases. Too little cell death can lead to the development of catastrophic diseases such as cancer and autoimmune diseases, while too much cell death can cause degenerative diseases. Therefore, a better understanding of each type of cell death is needed for basic research and medicinal purposes. As a trusted CRO, CD BioSciences now provides comprehensive solutions covering all aspects of life science research, including programmed cell death, ranging from Regulator Identification, Regulator Characterization, Mechanism Study, Phenotype Analysis, and Cell Death Characterization.

1. Regulator Identification identifies gene regulators participating in certain cell death signaling pathways.

2. Regulator Characterization studies the molecular function of certain regulators in cell death signaling pathways.

3. Mechanism Study investigates the mechanism of certain regulators.

4. Phenotype Analysis analyzes cellular phenotypes regulated by genes/proteins of interest.

5. Cell Death Characterization identifies and characterizes the types of cell death under certain conditions.

CD BioSciences is dedicated to assisting life science researchers focusing on cell death studies. For customers interested in more information regarding cell death solutions or other signaling pathways, please visit CD BioSciences at https://www.cd-biosciences.com.

About CD BioSciences

CD BioSciences is a trusted research product supplier and CRO based in New York. With high-quality reagents and comprehensive services, CD BioSciences is a one-stop shop devoted to advancing signaling pathway studies for researchers. The company is committed to fulfilling all demands in the research of signaling pathways and provides high-quality reagents and comprehensive solutions to support innovative discoveries.

Media Contact
Company Name: CD BioSciences
Contact Person: Michelle Moser
Email: Send Email
Phone: 1-315-636-4280
Country: United States
Website: https://www.cd-biosciences.com



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.